Seoul St. Mary's Hospital implements automated anticancer drug management system

Seoul St. Mary's Hospital has implemented a self-developed automated software system to manage the Risk Management Program (RMP) for certain anticancer drugs. The system was developed by Professor Lee Jeong-yeon’s team at the Hematology Hospital's Multiple Myeloma Center to reduce the repetitive administrative burden on medical staff.

Certain immunomodulatory drugs, such as thalidomide, lenalidomide, and pomalidomide, require strict RMP protocols due to the risk of fetal malformation. Previously, medical staff had to manually enter over 20 items for each new patient registration and repeat this process every 3 to 4 weeks for re-prescriptions. The new system automates the retrieval of patient details, diagnosis, and past prescription history using only a patient registration number.

To ensure patient safety, the system includes a double-approval structure where medical professionals must manually review and approve all data before final submission. It also features specific safeguards for female patients of childbearing age to ensure pregnancy test results are correctly registered. The software operates entirely on the hospital's internal network to protect personal information from external leaks. The research team is currently applying for patents and copyrights for the program.